CD19-directed CAR-T cells have already revolutionized the treatment of B-cell lymphomas and acute lymphoblastic leukemia, and their role in EBV-associated B-cell lymphomas parallels that seen in EBV-negative settings, such as CD19-positive diffuse large B-cell lymphoma (DLBCL) (61). Here, CD19 is linked to diffuse large B-cell lymphoma.